MabVax appoints Tom Varvaro to board
This article was originally published in Scrip
Executive Summary
MabVax Therapeutics, a clinical-stage cancer immunotherapy company, has named Tom Varvaro to its board of directors as an independent director. The appointment of Mr Varvaro brings the total number of directors to seven. Mr Varvaro, age 45, has served as the CFO of ChromaDex since January 2004 and served as a director from March 2006 until May 2010. At ChromaDex, he is responsible for overseeing all aspects of the company's accounting, IT, intellectual property, and human resources.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.